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Abstract 
It is well known that individuals who abuse drugs usually use more than one substance.  Toxic 
consequences of single and multiple drug use are well documented in the Treatment Episodes 
Data Set (TEDS) that lists combinations that result in hospital admissions.  Using this list as a 
guide, we focused our attention on combinations that result in the most hospital admissions and 
searched the PubMed database to determine the number of publications dealing with these toxic 
combinations.  Of special interest were those publications that looked for or used the term 
synergism in their titles or abstracts, a search that produced an extensive list of published articles.  
However, a further intersection of these with the term isobole revealed a surprisingly small 
number of literature reports.  Because the method of isoboles is the most common quantitative 
method for distinguishing between drug synergism and simple additivity, the small number of 
investigations that actually employed this quantitation suggests that the term synergism is not 
properly documented in describing the toxicity among these abused substances.  The possible 
reasons for this lack of quantitation may be related to a misunderstanding of the modeling 
equations.  The theory and modeling are discussed here. 
                   
1.  Introduction 
 
It is well known that alcohol, cocaine, opioids, marijuana, and various stimulants are prominent 
among substances that are frequently abused.  These substances have been extensively studied 
and the results of that effort are represented in a vast body of publications.  It is also well known 
that drug abusers do not usually confine their usage to a single drug.  In that regard, information 
from the Treatment Episode Data Set (TEDS) is revealing in that it provides drug combination 
data that resulted in hospital admissions due to drug abuse toxicity (Table 1).  The TEDS data are 
useful and emphasize the need for even more information on drug-drug interactions among the 
classes of abused drugs; of specific importance are those reactions that are synergistic.  
Therefore, it is of interest to ask whether drug synergism has been rigorously determined for 
pairs of abused substances.  Addressing that question is the main aim of this communication 
which also summarizes the theory that answers the question.  Our use of the TEDS database 
guided us in the selection of drug combinations of interest for our further data mining of 
substances that are of special interest.  Specifically, we examined the PubMed database to locate 
and count publications that include synergistic interactions for these widely abused drug 
combinations. 
 
1.1. Synergism and Isoboles: Key words in a search strategy 
 
A search strategy involves the use of key words and expressions that have special relevance to 
the search.  In that regard, we included the term synergism as a key word that describes supra-
additive interactions between two drugs.  Specifically, synergism refers to effects of the drug 
combination (toxic or beneficial) that are numerically greater than the combination effect that is 
suggested by the individual drug’s potency/efficacy profile.  This profile is determined from each 
drug’s dose-effect relation, where the “effect” is meant to be some common effect (therapeutic or 
toxic) that is produced by each.  The most common method for assessing synergism is the 
isobolographic method introduced and popularized by Loewe [1-3].  In this method one 
identifies a particular effect of interest that is common to each drug.  We then obtain the dose-
effect curve of each drug and from these we derive a third graph in Cartesian coordinates that 
plots dose pairs that are expected to yield the specified effect at some magnitude (often 50% of 
the maximum effect).  That third curve is the additive isobole.  Because each drug individually 
produces the specified effect, it is reasoned that the presence of one drug reduces the dose 
needed of the second drug in the production of the specified effect.  Therefore the graph of the 
dose of “drug B” against the dose of “drug A” is a monotone decreasing curve that may be linear 
or nonlinear.  This curve is termed the additive isobole (See Fig. 1). All points on the curve (drug 
dose pairs) are expected to produce the specified effect level and, therefore, experimental points 
found to be below the curve mean that lesser quantities are needed to produce the effect, thereby 
indicating a synergistic interaction.  Equivalently, synergism is indicated when a point (dose 
pair) on the isobole gives an effect that is greater than the specified effect for that isobole.  A 
point on the graph that plots above the isobole indicates a sub-additive interaction.  This 
graphical approach, which is highly dependent on the shape of the individual dose-effect curves, 
has been extensively examined and expanded.  Since the appearance of Loewe’s early works 
(op.cit.) there have appeared many theoretical and procedural details that are contained in more 
recent works and reviews [4-11].  The aim in all of these is the distinction between synergism 
and simple additivity or sub-additivity.  The terms synergism and isobole are therefore key words 
in our data mining procedure that is described below. 
 
2.  Methods 
 
Our search utilized 38 group substance names (GSNs) as listed in Table 2.  Some substance 
names included a wild card symbol to facilitate matching to various lexical forms of the same 
name.  Not all GSNs are disjoint; i.e., some were constructed as the unions of several other 
GSNs for which the PubMed query results were small.  We initially performed searches for each 
of the 38 GSNs.  For each of these a query was designed to return the PubMed identifier among 
all entries in that database that contain at least one of the substance names in either the title or 
abstract.  Thus, our first search strategy counted all papers that include the substance name in the 
title or abstract.  This strategy assumes that if one or more of the substances are a focus of the 
study, then their names will at least be mentioned in the title or abstract.  We proceeded by 
taking into account the co-occurrences of substances, e.g., in GSN #1 we used “buprenorphine or 
“buprenex.”  A further strategy counted papers that include pairs of substances from the different 
groups, while an additional strategy counted papers with pairs of substance names (from 
different groups) and either the term  “isobole” or “synergy” or “drug synergism.”  In order to 
further filter the search process we searched for pairs (from different groups) and “isobole or 
“synergy.”  The most refined final search included pairs of substance names and the term 
“isobole.” 
 
3.  Results 
 
We see from Table 1 that combinations of alcohol with marijuana and alcohol with cocaine 
account for the greatest percentage of hospital admissions.  Also notable are combinations of 
cocaine and marijuana, opioids and cocaine, and various CNS stimulants with alcohol.  This 
group of five pairs therefore became the main targets of our further exploration in regard to 
reports of synergism.  (It is interesting to note that tranquilizers and other sedative hypnotics are 
not high in number.)  Table 2 shows the 38 search terms that were used in a list that was derived 
from broad Drug Enforcement Administration categories consisting of narcotics, CNS 
depressants, stimulants, hallucinogens, cannabis, anabolic steroids, inhalants and alcohol.  A 
search of the PubMed database revealed that there are 447,074 published papers (as of February, 
2011) that include in their title or abstracts one or more names represented in this list of 38.  
Among this large number of reports the greatest number of publications were for category  #38 
alcohol (194,241), #30 testosterone (59,429), #17 benzodiazepines (41,120), #8 morphine 
(36,866),  #18 cocaine (25,397) and #29 marijuana (22,094).  Among the total of 447,074 papers 
there were 77,385 that included the term synergy or synergism in the title or abstract, and 1265 
papers that included the term isobole. When the search focused on publications that contain at 
least two substance names (in title or abstract) we found 59,957 publications.  Of these there 
were only 481 that contained either or both the terms isobole or synergy (synergism).  When 
confined to just the single term isobole, along with at least two substances, the number of 
publications dropped to 59. 
 
When the list of 38 is viewed against the five drug combinations that resulted in the most 
hospital admissions (shown in Table 1) we get the numbers of publications [12-16] shown in 
Table 3 that deal with these toxic combinations of interest.  Here we see a rather large number of 
publications involving alcohol with the several groups indicated.  Yet, among all of these, our 
search showed that the term isobole or isobolographic analysis is mentioned in only three 
publications with these combinations, specifically each with cocaine.  A somewhat similar result 
was found among the cocaine/marijuana publications.  Here there was only one paper, and there 
was only one paper dealing with cocaine and opioids.  These few are referenced in the table. 
 
4. Discussion 
 Our data mining effort was extensive and revealed a very large number of publications,  
both clinical and preclinical, that deal with the major drugs of abuse.  In our total database 
 more than 77,000 of these publications made reference to synergism.  This is a term that is 
 very frequently associated with the toxicity of drug combinations.  There is no doubt that drug 
combinations can be dangerous, whether the interaction is synergistic or simply additive.  Yet it 
is important to look more closely into the use of the term synergism, a word with a very specific 
quantitative meaning.  This kind of interaction should be used only if the drug combination has 
been subjected to a quantitative analysis that distinguishes between the observed combination 
effect and the effect that is expected from the individual drug potencies.  In most cases, and 
certainly among the drug groups mentioned here, an analysis of synergism almost always uses 
isobolographic methods.  Other methods of analysis such as response surface analysis [17, 5] 
have been used but are less common.  In that regard our data mining effort shows a drastic drop 
to only 59 publications that include the word isobole in the publication title or abstract.  Of 
course, it is possible that quantitation may have accompanied some of the papers that concluded 
synergism but just did not use the term isobole.  Therefore no firm conclusion can be drawn.  Yet 
the omission in the abstract of the method (isobole or other) that led to a conclusion of synergism 
seems unlikely if there really was a quantitative method used in the analysis.  This point is 
further reinforced by the magnitude of the drop:  over 77,000 papers mentioning synergism, but 
only 59 publications mentioning isobole.  Drug combinations can be very useful in therapy and 
drug combinations can be quite important in the production of toxic reactions.  Synergistic 
interactions are especially important in these cases of toxic reactions and also because this 
finding is often a first step in understanding mechanism, a fact well illustrated in the review by 
Tallarida and Raffa [11] that describes the basis of the various methods used in quantitating 
drug-drug interactions. 
 
The rather modest use of the term isobole (or employment of other quantitative methods) among 
the authors who use the term synergism may be due to some confusion that has surrounded the 
isobole method of analysis.  The source of this confusion may be due to the different views of its 
originator, Loewe, and a subsequent analysis by Berenbaum [4] that are summarized in the 
latter’s extensive review.  Loewe was clear in suggesting that the additive isobole could be 
nonlinear but he justified his view with a rather loose mathematical treatment that had 
cumbersome notation.  Berenbaum rejected Loewe’s reservations by providing an argument that 
included a sham demonstration that is described subsequently.  In short, Berenbaum took the 
linear equation x/A + y/B = 1 to be the definition of an additive interaction for a dose pair (x,y) 
with individual potencies A and B, respectively.  For example, if the specified effect level is 50% 
of the maximum, then A = ED50 of drug A and B = ED50 of drug B.  However, this is NOT the 
definition; it is, instead, a consequence of the fact that two agonist drugs have a constant relative 
potency as we now show.  In other words, dose x for drug A and dose y for drug B give a ratio R 
= A/B  (ratio of ED50’s) that is the same for all equally effective x,y  pairs.  In this case any tested 
dose x of drug A has a dose B-equivalent that is x/R.  From this it follows that the dose of drug B 
alone that gave the specified effect (that dose denoted B) could be achieved by adding the actual 
y and the equivalent, i.e., y + x/R = B.  On re-arrangement this becomes 
 
      x/A + y/B= 1.   (1) 
 
 If, however, the potency ratio R is not a constant, then equation (1) does NOT hold and the 
additive isobole will be generally nonlinear.  It is instructive to see how Berenbaum came to the 
conclusion that this linear relation defines the isobole.  His approach used a sham combination, 
i.e., only one agent and a dilution of that agent.  Those he considered as the two “drugs.”  From 
this he shows mathematically that the additive isobole is linear.  But that situation does not 
constitute a proof because the diluted drug and the actual drug will necessarily have a constant 
potency ratio, a situation in which the isobole is clearly linear as shown above.  If, however, the 
shapes of the individual dose-effect curves differ, (e.g., if the curves have different Emax values) 
then the potency ratio is not constant, and it is easy to show that the isobole is not linear [8-11].  
Hence, the Berenbaum assertion did not include the more general case of nonparallel dose effect 
curves, and therefore Loewe’s original assertion that isoboles can be nonlinear is correct.  The 
fact that isoboles can be (and often are) nonlinear should not detract from their usage in 
quantitating drug combinations since the nonlinear isobole represents no major mathematical 
challenge.  An interaction model or method that starts with the linear form above as the 
definition of additivity will be very restricted in its use.  Further, the confusion resulting from 
Berenbaum’s rejection of Loewe’s general case might explain, in part, the relatively small use of 
isoboles included among the many publications detected in our search.   
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 Fig. 1.  The smooth curve is an isobole, a monotone decreasing curve of dose pairs of drugs A 
and B that individually produce the same effect and which are used in combination in order to 
produce a specified effect level (usually 50% of the maximum).  The curve shows that the 
presence of the second drug reduces the needed dose of the first when both are present and there 
is no interaction between the two drugs, a situation termed “additive.”  The intercepts A and B 
denote the individual doses needed to achieve the effect.  The shape of the isobole (curvature) 
depends on the potency ratio of the two substances.  Regardless of its shape the isobole allows an 
assessment of synergism if the actual dose combination gives the effect with lesser quantities, 
such as point P, which falls below the curve.  In contrast, an actual dose pair above the isobole, 
such as point Q, indicates a sub-additive interaction. 
Table 1. Treatment Episode Data Set (TEDS) 
Below are substance abuse combinations by selected primary substance of abuse: TEDS number and 
percent distribution 
 
Primary substance Secondary and tertiary substances Number 
Percent of all 
admissions 
All admissions   1,882,584  100.0  
Alcohol    807,939   42.9  
No other substance n/a   444,781   23.6  
1 other substance Marijuana   117,272    6.2  
 Cocaine    87,674    4.7  
 Opiates    17,556    0.9  
 Stimulants    12,256    0.7  
  Other    12,027    0.6  
2 other substances Cocaine & Marijuana    53,499    2.8  
 Marijuana & Stimulants    16,047    0.9  
 Cocaine & Opiates    16,777    0.9  
 Marijuana & Opiates     6,285    0.3  
 Cocaine & Stimulants     4,400    0.2  
 Stimulants & Opiates     1,222    0.1  
 Marijuana & Other     9,460    0.5  
 Cocaine & Other     4,755    0.3  
 Opiates & Other     2,875    0.2  
  Stimulants & Other     1,053    0.1  
Cocaine     241,699   12.8  
No other substance n/a    71,123    3.8  
1 other substance Alcohol    70,520    3.7  
 Marijuana    23,074    1.2  
 Opiates     6,502    0.3  
 Stimulants     1,980    0.1  
  Other     2,362    0.1  
2 other substances Alcohol & Marijuana    44,874    2.4  
 Opiates & Alcohol     6,774    0.4  
 Stimulants & Alcohol     2,587    0.1  
 Opiates & Marijuana     2,748    0.1  
 Stimulants & Marijuana     2,065    0.1  
 Opiates & Stimulants       498   *  
 Alcohol & Other     3,349    0.2  
 Marijuana & Other     2,116    0.1  
 Opiates & Other       844   *  
  Stimulants & Other       283   *  
Opiates   331,272   17.6  
No other substance n/a 141,565    7.5  
1 other substance Cocaine  54,426    2.9  
 Alcohol  33,576    1.8  
 Marijuana  14,277    0.8  
 Stimulants   3,370    0.2  
  Other  10,950    0.6  
2 other substances Cocaine & Alcohol  30,630    1.6  
 Cocaine & Marijuana  12,733    0.7  
 Alcohol & Marijuana  10,741    0.6  
 Cocaine & Stimulants   2,871    0.2  
 Stimulants & Alcohol   1,743    0.1  
 Stimulants & Marijuana   1,265    0.1  
 Cocaine & Other   5,145    0.3  
 Alcohol & Other   4,777    0.3  
 Marijuana & Other   2,657    0.1  
  Stimulants & Other     546   *  
Marijuana   283,527   15.1  
No other substance n/a  99,870    5.3  
1 other substance Alcohol  99,531    5.3  
 Cocaine  11,046    0.6  
 Stimulants   9,959    0.5  
 Opiates   2,280    0.1  
  Other   5,752    0.3  
2 other substances Alcohol & Cocaine  18,817    1.0  
 Alcohol & Stimulants  13,561    0.7  
 Stimulants & Cocaine   2,339    0.1  
 Alcohol & Opiates   3,169    0.2  
 Cocaine & Opiates   1,386    0.1  
 Stimulants & Opiates     523   *  
 Alcohol & Other  11,022    0.6  
 Cocaine & Other   1,926    0.1  
 Stimulants & Other   1,445    0.1  
  Opiates & Other     901   *  
Stimulants   126,063    6.7  
No other substance n/a 37,773    2.0  
1 other substance Alcohol 19,137    1.0  
 Marijuana 21,707    1.2  
 Cocaine  3,052    0.2  
 Opiates  1,396    0.1  
  Other  1,625    0.1  
2 other substances Marijuana & Alcohol 25,135    1.3  
 Cocaine & Alcohol  4,233    0.2  
 Cocaine & Marijuana  4,314    0.2  
 Opiates & Alcohol  1,280    0.1  
 Marijuana & Opiates  1,333    0.1  
 Cocaine & Opiates    763   *  
 Marijuana & Other  2,032    0.1  
 Alcohol & Other  1,444    0.1  
 Cocaine & Other    519   *  
  Opiates & Other    320   *  
Other   92,084    4.9  
 
 
SOURCE: The Treatment Episode Data Set (TEDS) is maintained by the Office of Applied Studies, 
Substance Abuse and Mental Health Services Administration (SAMHSA). The TEDS system includes 
records for some 1.5 million substance abuse treatment admissions annually. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE 2. DRUGS OF ABUSE  
Source: U.S. Department of Justice Drug Enforcement Administration 
 
  Term(s) 
PubMed search count* 
(Title and/or Abstract, 
unless stated otherwise) 
1 buprenorphine, buprenex 3,210
2 butorphanol, stadol 1,029
3 codeine 3,409
4 fentanyl, duragesic 12,089
5 hydrocodone, vicodin 397
6 hydromorphone, dilaudid 801
7 methadone, dolophine 8,715
8 morphine, astramorph 36,866
9 oxycodone, oxycontin 1,154
10 propoxyphene, darvon 828
11 mephobarbital, mebaral 81
12 pentobarbital, nembutal 13,000
13 diazepam, valium 16,838
14 chlordiazepoxide, librium 2,919
15 alprazolam, xanax 1,752
16 lorazepam, ativan, temesta 2,712
17 
benzodiazepine*, diazepam, 
valium, chlordiazepoxide, librium, 
alprazolam, xanax, lorazepam, 
ativan, temesta 41,120
18 cocaine 25,397
19 phentermine 407
20 diethylpropion 194
21 
methamphetamine, 
dextroamphetamine 6,579
22 
methylphenidate, 
dexmethylphenidate, ritalin, 
adderall 4,300
23 caffeine 19,365
24 ketamine 10,380
25 
mdma, 
methylenedioxyamphetamine 2,709
26 lsd, lysergic acid 4,137
27 
mescalin, 
trimethoxyphenethylamine, 
phenethylamine 590
28 psilocybin 321
29 
tetrahydrocannabinol, thc, cannab*, 
marijuana 22,094
30 testosterone, dihydrotestosterone 59,429
31 nitrous oxide 11,539
32 alkyl nitrites 46
33 amyl nitrite 428
34 butyl nitrite 60
35 isopropyl nitrite 9
36 isobutyl nitrite 79
37 
inhalant*, nitrous oxide, alkyl 
nitrites, amyl nitrite, butyl nitrite, 
isopropyl nitrite, isobutyl nitrite 14,969
38 alcohol 194,241
 
*In the above the column total is 524,193.  When corrected for duplicates the sum is 447,074 as reported 
in the text. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Number of publications of the named drug and combinations using 
isoboles 
 
Combination   Relevant Publications   Isobolar analysis 
 
Alcohol with marijuana  4326 out of 11589    0 
(#38 with #29)   (on alcohol & other drugs) 
 
 
Alcohol with cocaine  3245 out of 11589    3[12-14] 
( #38 with #18)   (on alcohol and other drugs) 
 
Alcohol + other  stimulants 1691 out of 11589    0 
(#38 with #19-25)  (on alcohol and other drugs) 
 
 
Cocaine with marijuana  2435 out of 7516    1[15] 
( #18 with #29)   (cocaine and other drugs) 
 
 
Cocaine with opioids  2015 out of 7516    1[16] 
( #18 with #3-9)   (cocaine and other drugs)  
 
 
